Author | Shaji Kumar, MD | OncLive

Author | Shaji Kumar, MD

Articles

Dr. Kumar on the Rationale Behind the ENDURANCE Trial in Newly Diagnosed Myeloma

July 10, 2020

Shaji Kumar, MD, discusses the rationale behind the phase 3 ENDURANCE trial, which is comparing carfilzomib, lenalidomide, and dexamethasone with bortezomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.

Dr. Kumar on Utility of ASCT in Newly Diagnosed Multiple Myeloma

February 22, 2019

Shaji Kumar, MD, of Mayo Clinic, advises physicians on the use of autologous stem cell transplant in patients with newly diagnosed multiple myeloma.

Dr. Kumar on Updates to Treatment for Patients With High-Risk Myeloma

November 09, 2017

Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses updates to the treatment paradigm of high-risk multiple myeloma in an interview during the 2017 Chemotherapy Foundation Symposium.

Dr. Kumar on Potential of CAR T-Cell Therapy in Multiple Myeloma

May 02, 2017

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of multiple myeloma.

x